Sarepta Therapeutics (NASDAQ:SRPT) versus Mirum Pharmaceuticals (NASDAQ:MIRM) Head to Head Survey

Sarepta Therapeutics (NASDAQ:SRPT) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

86.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Sarepta Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Profitability

This table compares Sarepta Therapeutics and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Earnings & Valuation

This table compares Sarepta Therapeutics and Mirum Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$1.97 billion	1.00	-$713.41 million	($2.90)	-6.42
Mirum Pharmaceuticals	$521.31 million	11.07	-$23.36 million	($14.55)	-6.11

Mirum Pharmaceuticals has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Sarepta Therapeutics and Mirum Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6	5	8	0	2.11
Mirum Pharmaceuticals	1	0	13	1	2.93

Sarepta Therapeutics presently has a consensus target price of $24.07, suggesting a potential upside of 29.36%. Mirum Pharmaceuticals has a consensus target price of $137.31, suggesting a potential upside of 54.48%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Sarepta Therapeutics.

Summary

Mirum Pharmaceuticals beats Sarepta Therapeutics on 9 of the 15 factors compared between the two stocks.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.